Investigation of 1,2,4-Triazole Derivatives as Potantial Anti-Diabetic Agents: In vitro Enzyme Inhibition and In silico Pharmacokinetic Studies
Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi, cilt.16, sa.2, ss.345-356, 2023 (TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 16 Sayı: 2
- Basım Tarihi: 2023
- Doi Numarası: 10.18185/erzifbed.1216717
- Dergi Adı: Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
- Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.345-356
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Karadeniz Teknik Üniversitesi Adresli: Evet
Özet
Diabetes mellitus (DM) is a metabolic disease that causes an increase in blood glucose levels, leading to postprandial hyperglycemia and numerous secondary problems, such as kidney failure, blindness, cardiovascular diseases, and nerve damage. Inhibitors of α amylase and α glucosidase are widely used in the treatment of type-II DM because they can inhibit the digestion of starch. In this study, the inhibition potentials of previously synthesized fluorine-containing 1,2,4-triazole-5-one derivatives (4a-d, 6a-b, 7a-b, 8a-b) were screened against α-amylase and α-glucosidase activities. All the compounds exhibited varying degrees of α- amylase inhibitory potential, ranging from 185.2 ± 3.4 to 535.6 ± 5.5 μM. For α-glucosidase, the IC50 values ranged from 202.1 ± 3.8 to 803.2 ± 10.3 μM, compared to the positive control acarbose (IC50 = 411.3 ± 6.4 μM for α-amylase and IC50 = 252.0 ± 4.8 μM for α-glucosidase). 4c exhibited excellent inhibitory potential in both cases, and we evaluated the mode of inhibition of α-amylase and α-glucosidase through kinetic studies. Furthermore, we calculated the physicochemical and pharmacokinetic properties of molecule 4c using SwissADME software. The results of our research suggest that compound 4c may be a promising candidate for the treatment of type-II DM.